Contact

Translational Neuroscience 2017 : registrations are open !

Registrations for the first edition of « Translational neuroscience : challenges and opportunities » are now open !

NeurATRIS and Medicen Paris Région are very happy to invite you to this event on November 20, 2017, at the Cité Universitaire Internationale de Paris.

Gathering experts in neurodegenerative diseases, this event will foster interactions between researchers, clinicians, biotech and pharmaceutical companies.

You will be able to:

  • Meet researchers and clinicians with cutting edge expertise in neurodegenerative diseases
  • Hear pharmaceutical companies presenting their views and needs
  • Share your assets and needs in a flash during a pitch session
  • Build R&D collaborative projects during a matchmaking session

Online registration is free and mandatory before November 5 : https://tranlational-neuroscience.b2match.io/

Looking forward to seeing you there !

Save the date ! November 20, 2017 - Translational Neuroscience in Paris

NeurATRIS and Medicen Paris Région are very happy to invite you to the first edition of “Translational neuroscience: challenges and opportunities”, on November 20, 2017, at the Cité Universitaire Internationale de Paris.

Gathering experts in neurodegenerative diseases, this event will foster interactions between researchers, clinicians, biotech and pharmaceutical companies.

You will be able to:

  • Meet researchers and clinicians with cutting edge expertise in neurodegenerative diseases
  • Hear pharmaceutical companies presenting their views and needs
  • Share your assets and needs in a flash during a pitch session
  • Build R&D collaborative projects during a matchmaking session

Looking forward to seeing you there !

 

Translational Medicine '17 - Prague, September 24-26, 2017

The European Research Infrastructure for Translational Medicine (EATRIS) organizes its third bi-annual conference, “Translational Medicine 2017” on September 24-26 2017 at Corinthia Hotel in Prague.

This event, open to a wide range of stakeholders from academic researchers, funders to industry players and regulators, will bring together international experts to discuss the latest advancements in translational medicine.

The theme of this third edition, “Enhancing Predictivity in Medicines Development” will focus on bringing together the latest technologies to increase success in drug development, from novel in vitro systems to new biomarkers or clinical trial methodology for patient selection and stratification.

For this year’s edition, you will hear from – among others – Mark Schmidt (Senior Director, Janssen Research and Development), Philip Murphy (Head, Experimental Medicine Imaging, GSK), Christopher Austin (NIH-NCATS, United States). Find out all about the conference’s keynote speakers.

The programme also includes a pre-conference day on Sunday, September 24, that will be dedicated to a series of educational workshops tackling topics in the field such as molecular imaging, biomarker validation or potency assays for ATMP’s and vaccines.

Translational Medicine 2017 also welcomes abstract submissions until May 15, 2017!

For more information, please visit: www.translationalmedicine2017.eu

Questions? Send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

NeurATRIS will attend this event, do not hesitate to This email address is being protected from spambots. You need JavaScript enabled to view it. us to set up a meeting.

Prediction of cognition in Parkinson's disease 10 years after onset

Cognitive decline is one of the most debilitating manifestations of disease progression in Parkinson's disease and is a key determinant of a patient's quality of life and independence.1 The ability to predict and to manage this complication is highly relevant for recruitment into and stratification of clinical trials, particularly those designed to slow disease progression and to prevent dementia. Although a multitude of drugs for Parkinson's disease is available to improve motor aspects of the disease, these do not have a major effect on cognitive decline.

The authors of a study published in The Lancet Neurology aimed to develop a clinical–genetic score to predict global cognitive impairment in patients with the disease. This international study involving clinicians from AP-HP, Inserm, UPMC at ICM was conducted using 9 cohorts gathering 3200 patients. The resulting predictive algorithm provides a potential test for future cognitive health or impairment in patients with Parkinson's disease. This model could improve trials of cognitive interventions and inform on prognosis.

In France, the DIG-PD cohort, coordinated by Pr Jean-Christophe Corvol at ICM, followed more than 400 patients for 6 years.